Smaller Potential of the Personal | GenomeWeb

Personalized medicine of the "the right drug for the right patient at the right time" ethos may help patients, but Forbes' Henry Miller writes that it might not be right for drug companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Cancer Trial Halted

Promising Trial

Edits Eyed

Changes Ahead

Down the Road a Ways

And, Poof, It's Gone

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.